Virometix: US$15m for Synthetic Vaccines

Virometix AG, based in Schlieren, has closed a US$15m financing round from existing shareholders, underscoring continued investor confidence in its fully synthetic vaccine technology. The funds will support clinical progress of V-212, a serotype-independent pneumococcal vaccine now in Phase I testing, and enable further enhancements to the company’s Synthetic Virus-Like Particle (SVLP) platform.

CEO Anna Sumeray said the investment reflects growing recognition of Virometix’s approach. “Our fully synthetic SVLP technology enables the design of broad-spectrum, self-adjuvanted vaccines with highly scalable manufacturing,” she commented. “With V-212 in clinical development, we’re well positioned to deliver a truly next-generation approach to pneumococcal prevention.”

V-212 is designed to protect against Streptococcus pneumoniae by targeting conserved antigenic regions found across multiple serotypes. Unlike traditional conjugate vaccines, Virometix’s candidate is built entirely through chemical synthesis, eliminating reliance on biological carrier proteins and simplifying production. Early studies have shown strong and durable immune responses across several pneumococcal strains.

The Phase I trial is evaluating safety and immunogenicity in 60 healthy adults aged between 18 and 45, with topline results expected in early 2026.

Founded in Switzerland in 2009, Virometix is developing a new generation of synthetic vaccines aimed at infectious diseases and cancer. Its SVLP platform integrates rational molecular design with chemical synthesis to create vaccine candidates that promise high safety, efficacy and scalability – and could help reshape how complex vaccines are made.